Facilitating the Adoption of Evidence-Based Depression Management in Substance Use Treatment Programs
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00137306|
Recruitment Status : Completed
First Posted : August 29, 2005
Last Update Posted : April 7, 2015
|Condition or disease||Intervention/treatment||Phase|
|Mood Disorders Substance-Related Disorders||Procedure: Facilitate evidence-based treatment for depression||Phase 4|
Comorbid depression has been consistently linked to worse outcomes for patients in substance abuse treatment programs. Practice guidelines recommend pharmacotherapy for comorbid depression if symptoms persist after a 4-week "wash-out" period for detoxification (e.g., Veterans Health Administration; American Psychiatric Association). Medications may be considered earlier if a patient has current symptoms and a history of major depressive disorder (MDD) during periods of sobriety. Current efficacy data suggest that antidepressant medication can improve both depression and substance use outcomes among comorbid patients Guideline-concordant use of antidepressant medication for persons with comorbid substance use and depressive disorders, however, is not routine in many VA substance abuse treatment settings.
This study seeks to develop, implement, and test an organizational intervention in VA substance abuse treatment settings to establish guideline-concordant treatment of comorbid depression. The intervention will assist "intervention" programs in their own implementation of a guidelines-based treatment algorithm to improve the recognition of depression and initiation of pharmacotherapy.
Substance abuse treatment programs in the South Central VISN were matched on program characteristics and current depression management practices (n = 4), and "intervention" sites were randomly chosen from each pair. Phase 1 (now completed) of the study analyzed the barriers and facilitators to translation of depression management in participating facilities, and used these data to inform the development of the translation intervention, its implementation tools, and the depression algorithm. The translation intervention adopted in this plan was based on the PRECEDE model of organizational behavior change and included provider education, use of local champions, feedback of screening data, and patient education/activation. The depression management algorithm and intervention was developed with input from programs staff and an Advisory Panel of depression management and translation experts. Phase 2 of the study implemented and tested the intervention. The evaluation in examining program- and provider-level outcomes. Program-level outcomes include feasibility, extent of adoption of the algorithm, and provider/organizational attitudes and beliefs about the intervention's design and effectiveness. Patient-level outcomes include depressive symptoms, substance use outcomes, medication adherence, quality of life, and services use.
Phase 1 of the study is complete. Phase 2 is near complete.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||300 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Translating Depression Guidelines Into Substance Abuse Treatment|
|Study Start Date :||January 2004|
|Actual Primary Completion Date :||October 2006|
|Actual Study Completion Date :||October 2006|
|Arm 1||Procedure: Facilitate evidence-based treatment for depression|
- Program: extent, quality of adoption of protocolPatient: scores on-depression, substance use, and functioning scales
- Programs: Staff satisfaction with protocol/intervention Patients: medication adherence
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00137306
|United States, Arkansas|
|Central Arkansas Veterans Healthcare System Eugene J. Towbin Healthcare Center, Little Rock, AR|
|No. Little Rock, Arkansas, United States, 72114-1706|
|United States, Louisiana|
|Southeast Louisiana Veterans Health Care System, New Orleans, LA|
|New Orleans, Louisiana, United States, 70112|
|United States, Mississippi|
|VA Gulf Coast Veterans Health Care System|
|Biloxi, Mississippi, United States, 39531|
|G.V. (Sonny) Montgomery VA Medical Center, Jackson, MS|
|Jackson, Mississippi, United States, 39216|
|United States, Oklahoma|
|Oklahoma City, OK|
|Oklahoma City, Oklahoma, United States, 73104|
|Principal Investigator:||Geoffrey M. Curran, PhD||Central Arkansas Veterans Healthcare System Eugene J. Towbin Healthcare Center, Little Rock, AR|